AffaMed is a late clinical-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs in ophthalmology. self-described.

AffaMed

AffaMed Therapeutics | 1,440 followers on LinkedIn. To Become a Leading Ophthalmology and CNS Company with Innovative Therapeutics and Solutions for China and the World. | AffaMed Therapeutics is a clinical stage therapeutic company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development at leading multi-national pharmaceutical companies in China and globally.

Innovation & Digital Health

Lingyun (Wendy) Mao

Director of Clinical Operation

Roger Liu

Research in opthalmology

Annie Yang

Chief Regulatory Officer, Global Regulatory Science - AffaMed Therapeutics (a Biotech company)

Rose Yu

AffaMed Therapeutics

As the first NDA filing by AffaMed Therapeutics , the acceptance of our DEXTENZA NDA in Singapore represents an important milestone in our company’s journey. AffaMed is developing DEXTENZA as the first physician-administered sustained-release intracanalicular insert available to patients in the ASEAN countries and Greater China for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. For more information please visit : https://lnkd.in/gRrgAKu8 #ophthalmology #cataract #allergicconjunctivitis

Happy Chinese New Year！ AffaMed Therapeutics wishes all our friends and relationships health, wealth and happiness in the new Year of the Dragon! 新春快乐！蔼睦医疗恭祝您和您的家人龙行大运，平安喜乐！

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 18, 2024 10:01 PM	2f20f51a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 18, 2024 10:01 PM	56dc3b24
crunchbase trigger	general	Nov 18, 2024 10:01 PM	476e4873
crunchbase profile	general
li profile	general	Nov 18, 2024 10:01 PM	9769d87d
translate crunchbase fundingrounds	general
peers	general	Nov 18, 2024 10:01 PM	ccaba358
news basic	general	Nov 18, 2024 10:01 PM	35667589
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AFFA

COM:AFFAMED

AffaMed